Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase…
Dark genome biotech company RyboDyn closes pre-seed fundraise from leading global investors to advance cancer immunotherapy SAN DIEGO, Jan. 9,…
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE…
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a…
Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the "Company") on (i)…
The VENTANA DP 600 slide scanner, part of Roche's Digital Pathology Dx system, is now cleared by the FDA to…
LAS VEGAS, Jan. 8, 2025 /PRNewswire/ -- The Industrial Technology Research Institute (ITRI) initiated its presence at CES 2025 with an…
Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE)…
Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract…
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/…